 SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 PRNewswire -- Ascentage Pharma 6855.HK, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B CHB, and age-related diseases, today announced that its global licensee, UNITY Biotechnology, Inc. UNITY, NASDAQ:UBX, has reported encouraging data from a Phase I clinical study of UBX1325, an investigational Bcl-xL inhibiting compound, in patients with certain advanced vascular eye diseases, and has already dosed the first patient in the subsequent Phase IIa clinical study. 